StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Intercept Pharma's (ICPT) OCA wins FDA panel backing in PBC
April 7, 2016 3:49 PM
(Updated - April 7, 2016 3:51 PM EDT)Intercept Pharma ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
FDA
Hot FDA News
Trader Talk
Next Articles
FBR Capital Remains on Sidelines with Intercept Pharmaceuticals (ICPT) Following FDA Panel Backing
April 8, 2016 9:51 AM
Oppenheimer Reiterates $309 PT on Intercept Pharma (ICPT) Following FDA Panel Backing
April 8, 2016 8:25 AM
Wedbush Reiterates Outperform, $423 PT on Intercept (ICPT) Following FDA Panel Backing
April 8, 2016 7:56 AM
Panel Backing of OCA was Expected, Leerink Partners Says; Remains Sidelined
April 8, 2016 7:34 AM
Morgan Stanley Cuts Intercept (ICPT) to Underweight on Ocaliva Label/Launch Concerns, NASH Read-Through
April 8, 2016 6:56 AM
Needham & Company Reiterates Buy on Intercept Pharma (ICPT) Following Positive FDA Panel Vote on Obeticholic Acid
April 8, 2016 6:53 AM
Intercept Pharma (ICPT) to Resume Trading at 5:30 PM ET
April 7, 2016 5:05 PM
Intercept (ICPT) Announces Unanimous FDA Committee Recommendation for Accelerated Approval of OCA as PBC Treatment
April 7, 2016 5:02 PM
